Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Market Cap	$6.00B	P/E Ratio	36.13
52W High	$107.84	52W Low	$49.38
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	7.6%	52W Position	96.6%
Overall Score	46	Value Score	50
Quality Score	60	Technical Score	30

EPS Current Est	$2.93	EPS Next Est	$-1.33
EPS Growth Est	-145.4%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTGX	$105.87	+8.00%	876.52K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTGX	$105.87	+8.0%	876.52K
3
4
5
6

PTGX

PTGX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Protagonist Therapeutics Inc. Data in Excel

Get Protagonist Therapeutics Inc. Data in Excel